Details of the Drug

General Information of Drug (ID: DMH0ZJE)

Drug Name

Mitomycin

Synonyms

Mitomycin C; mitomycin C; 1950/7/7; Mutamycin; Ametycine; Mitocin-C; Ametycin; Mitomycin-C; Mytozytrex; Mitomycinum; Mytomycin; Mitozytrex; Mitomycinum C; Mitocin C; Mitomycins; Mitamycin; MMC; Mitosol; Mitomycyna C; 7-Amino-9alpha-methoxymitosane; NSC-26980; Mitomycyna C [Polish]; Mito-C; Mit-C; Mitomycin (TN); Mitomycinum [INN-Latin]; Mitomycine [INN-French]; Mitomicina [INN-Spanish]; NCI-C04706; RCRA waste number U010; NSC26980; NSC 26980; Mitomycine; CCRIS 414; UNII-50SG953SK6; HSDB 3239; C15H18N4O5; EINECS 200-008-6; Mitomycin C,; Ametycin; Mitomicina; Muamycin; Mitomycin C from Streptomyces caespitosus; Mitomycin C (JP15); Mitomycin C, Streptomyces caespitosus; Muamycin (TN); Mitomycin (USP/INN); Mitomycin [USAN:INN:BAN]; Mitomycin C, Streptomyces caespitosus, Carrier-Free

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[1], [2]
Gastrointestinal cancer	2C11	Approved	[1], [2]
Solid tumour/cancer	2A00-2F9Z	Approved	[2]

Therapeutic Class

Anticancer Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

334.33

Topological Polar Surface Area (xlogp)

-0.4

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption: The drug is unstablely absorbed [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 8 - 48 minutes [4]
Metabolism: The drug is metabolized via the hepatic [3]

Chemical Identifiers

Formula: C15H18N4O5
IUPAC Name: [(4S,6S,7R,8S)-11-amino-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate
Canonical SMILES: CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)N
InChI: InChI=1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1
InChIKey: NWIBSHFKIJFRCO-WUDYKRTCSA-N

Cross-matching ID

PubChem CID: 5746
ChEBI ID: CHEBI:27504
CAS Number: 50-07-7
DrugBank ID: DB00305
TTD ID: D0Y0GH
VARIDT ID: DR01212
ACDINA ID: D01255

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human Deoxyribonucleic acid (hDNA)	TTUTN1I	NOUNIPROTAC	Binder	[5], [6]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[7]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Mitomycin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Mitomycin and Roflumilast.	Asthma [CA23]	[24]
Ofloxacin	DM0VQN3	Minor	Decreased absorption of Mitomycin due to intestinal mucosa variation caused by Ofloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Ciprofloxacin XR	DM2NLS9	Minor	Decreased absorption of Mitomycin due to intestinal mucosa variation caused by Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[25]
Trovafloxacin	DM6AN32	Minor	Decreased absorption of Mitomycin due to intestinal mucosa variation caused by Trovafloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Sparfloxacin	DMB4HCT	Minor	Decreased absorption of Mitomycin due to intestinal mucosa variation caused by Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Gemifloxacin	DMHT34O	Minor	Decreased absorption of Mitomycin due to intestinal mucosa variation caused by Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Norfloxacin	DMIZ6W2	Minor	Decreased absorption of Mitomycin due to intestinal mucosa variation caused by Norfloxacin.	Bacterial infection [1A00-1C4Z]	[25]
ABT-492	DMJFD2I	Minor	Decreased absorption of Mitomycin due to intestinal mucosa variation caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[25]
Levofloxacin	DMS60RB	Minor	Decreased absorption of Mitomycin due to intestinal mucosa variation caused by Levofloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Lomefloxacin	DMVRH9C	Minor	Decreased absorption of Mitomycin due to intestinal mucosa variation caused by Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Grepafloxacin	DMGLX0T	Minor	Decreased absorption of Mitomycin due to intestinal mucosa variation caused by Grepafloxacin.	Bronchitis [CA20]	[25]
Teriflunomide	DMQ2FKJ	Major	Additive immunosuppressive effects by the combination of Mitomycin and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[26]
Denosumab	DMNI0KO	Moderate	Additive myelosuppressive effects by the combination of Mitomycin and Denosumab.	Low bone mass disorder [FB83]	[27]
Thalidomide	DM70BU5	Major	Additive thrombogenic effects by the combination of Mitomycin and Thalidomide.	Multiple myeloma [2A83]	[28]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Mitomycin and Tecfidera.	Multiple sclerosis [8A40]	[29]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Mitomycin and Siponimod.	Multiple sclerosis [8A40]	[30]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Mitomycin and Fingolimod.	Multiple sclerosis [8A40]	[31]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Mitomycin and Ocrelizumab.	Multiple sclerosis [8A40]	[32]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Mitomycin and Ozanimod.	Multiple sclerosis [8A40]	[24]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Mitomycin and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[33]
Gatifloxacin	DMSL679	Minor	Decreased absorption of Mitomycin due to intestinal mucosa variation caused by Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[25]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Mitomycin and Canakinumab.	Rheumatoid arthritis [FA20]	[34]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Mitomycin and Rilonacept.	Rheumatoid arthritis [FA20]	[34]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Mitomycin and Golimumab.	Rheumatoid arthritis [FA20]	[35]
Leflunomide	DMR8ONJ	Major	Additive immunosuppressive effects by the combination of Mitomycin and Leflunomide.	Rheumatoid arthritis [FA20]	[26]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Mitomycin when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[36]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Mitomycin due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[37]
Azathioprine	DMMZSXQ	Moderate	Additive immunosuppressive effects by the combination of Mitomycin and Azathioprine.	Transplant rejection [NE84]	[30]
Cinoxacin	DM4EWNS	Minor	Decreased absorption of Mitomycin due to intestinal mucosa variation caused by Cinoxacin.	Urinary tract infection [GC08]	[25]
Nalidixic acid	DMRM0JV	Minor	Decreased absorption of Mitomycin due to intestinal mucosa variation caused by Nalidixic acid.	Urinary tract infection [GC08]	[25]
Enoxacin	DMYTE6L	Minor	Decreased absorption of Mitomycin due to intestinal mucosa variation caused by Enoxacin.	Urinary tract infection [GC08]	[25]
Ganciclovir	DM1MBYQ	Moderate	Increased risk of nephrotoxicity by the combination of Mitomycin and Ganciclovir.	Virus infection [1A24-1D9Z]	[30]
Valganciclovir	DMS2IUH	Moderate	Increased risk of nephrotoxicity by the combination of Mitomycin and Valganciclovir.	Virus infection [1A24-1D9Z]	[30]
-----------


⏷ Show the Full List of 33 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Hypromellose	E00634	Not Available	Coating agent
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Water	E00035	962	Solvent
Hydroxyethyl-beta-cyclodextrin	E00631	Not Available	Other agent
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Mitomycin 40mg/vial powder	40mg/vial	Powder	Pyelocalyceal
Mitomycin 0.2mg/vial For solution	0.2mg/vial	For Solution	Topical
Mitomycin 5mg/vial injectable	5mg/vial	Injectable	Injection

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7089).
2	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	Assessment of cell viability, lipid peroxidation and quantification of DNA fragmentation after the treatment of anticancerous drug mitomycin C and ... Exp Toxicol Pathol. 2010 Sep;62(5):503-8.
6	Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther. 1999 Sep;83(3):181-215.
7	In vivo expansion of MDR1-transduced cells accompanied by a post-transplantation chemotherapy regimen with mitomycin C and methotrexate. J Gene Med. 2010 Jul;12(7):596-603.
8	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
9	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
10	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
11	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
12	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
13	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
14	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
15	Cisplatin and DNA repair in cancer chemotherapy.Trends Biochem Sci.1995 Oct;20(10):435-9.
16	Structures of oxaliplatin-oligonucleotide adducts from DNA.J Mass Spectrom.2012 Oct;47(10):1282-93.
17	31P NMR spectra of ethidium, quinacrine, and daunomycin complexes with poly(adenylic acid).poly(uridylic acid) RNA duplex and calf thymus DNA. Biochemistry. 1989 Apr 4;28(7):2804-12.
18	Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer. 2005 May 9;92(9):1626-35.
19	O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int J Cancer. 1998 Sep 11;77(6):919-22.
20	Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Clin Cancer Res.2010 Oct 1;16(19):4899-905.
21	DNA intrastrand cross-link at the 5'-GA-3' sequence formed by busulfan and its role in the cytotoxic effect. Cancer Sci. 2004 May;95(5):454-8.
22	Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations... DNA Repair (Amst). 2009 Jan 1;8(1):72-86.
23	Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mono... Melanoma Res. 2011 Dec;21(6):502-8.
24	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
25	Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
26	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
27	Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
28	Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
29	Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
30	Cerner Multum, Inc. "Australian Product Information.".
31	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
32	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
33	Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
34	Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
35	Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
36	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
37	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.